Abstract Body

Background: Inflammation is associated with increased morbidity and mortality in HIV-infected individuals. Microbial translocation may be a major driver of this inflammation. Sevelamer carbonate, a phosphate binder, decreases serum lipopolysaccharide (LPS), low-density lipoprotein (LDL) cholesterol, and inflammatory markers in hemodialysis patients. We hypothesized that sevelamer would reduce circulating LPS and monocyte and T cell activation in HIVinfected subjects. Methodology: In this single arm study, HIV-infected participants not on antiretroviral therapy (ART) received sevelamer 1600 mg three times a day for 8 weeks and were followed for an additional 8 weeks off treatment. Circulating soluble CD14 (sCD14), LPS, IL-6, D-dimer, C-reactive protein (CRP), fetuin A, IL-1β, IP-10, soluble CD163 (sCD163), soluble tissue factor (sTF), and oxidized LDL (oxLDL) cholesterol were measured in centralized labs, and total, non-HDL, and LDL cholesterol at local research sites. HLA-DR+CD38+ and Ki67+ CD4 and CD8 T cells were measured by flow cytometry in a central lab. Statistical significance of changes in measurements between time points was determined using the sign test. Results: 40 participants were enrolled; 4 were excluded from analysis because of missing key visits (n=3) or ART initiation (n=1). Of 36 evaluable participants, 72% were male; median age was 44 years; median CD4+ T cell count 585/mm3; median HIV-1 RNA 3800 copies/mL. Phosphate levels did not change significantly; 7 participants received phosphate supplementation per protocol due to serum phosphate <2.5 mg/dL; there were no other adverse events. Key results are shown in the table. LPS, sCD14, CD4+ T cell counts, and HIV-1 RNA levels did not change significantly with or after treatment. The frequency of HLA-DR+ CD4 T cells or Ki67+ CD4 or CD8 T cells or fetuin A, IL-1β, IP-10, or sCD163 levels did not change significantly during or after treatment. Conclusions: In HIV-infected participants not on ART, sevelamer for 8 weeks does not appear to decrease microbial translocation or immune activation but appears to decrease LDL, oxLDL, and sTF. OxLDL induces TF expression in numerous cell types; sevelamer may reduce TF by decreasing OxLDL, suggesting that it might have beneficial cardiovascular effects. Further investigation into the effects of sevelamer on the coagulation cascade, including the biological relevance of the modest increase in D-dimer levels, is warranted.